Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development Overview
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEW
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEW
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEW
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm. IQVIA and Apple are collaborating to bring this exciting future of personalized care directly to devices patients already have and use.
LEARN MOREOur mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORECareers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE
"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSThe sale of prescription drugs in the United States (U.S.) is regulated by a comprehensive set of federal and state laws. Online pharmacies are accredited by the National Association of Boards of Pharmacy (NABP) and need to follow precise rules of practice. Illegal online pharmacies (IOPs) are those that operate online without the requisite valid licenses or supply drugs not approved by the FDA.
The purpose of this report is to summarize the results of research into the nature and use of illegal online pharmacies (IOPs) over recent years and the impact this has on public health and the operation of the distribution system. The research draws on a novel methodology developed by IE University and commercialized by Translucent Datalab (www.translucentdatalab.com), a technology spin-off from IE University, to profile the network of IOPs that are being accessed from the U.S. and used to order prescription medicines. This methodology is part of a project that has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement No 715536). The IQVIA Institute has collaborated with Translucent Datalab in the development of this report.
This methodology identified 19,013 IOPs (15,501 active and 3,512 inactive) as of March 2023. An estimated total of 416 million prescriptions were provided to patients by these IOPs between January 2017 and December 2022. Between 2019 and 2022, the number of prescriptions dispensed annually through IOPs increased from 64 million to 85 million at a compounded annual growth rate of 10%.
Out of the top 30 therapeutic categories by legal prescription volume, those categories with the highest volume share being sold through IOPs included drugs used as part of cancer treatment (including hormone therapies) at 10.4% of total volume; sex hormones 5.5%; dermatologics 3.4%; other cardiovascular drugs (including those used for erectile dysfunction) 3.7%; hormonal contraception, systemic and topical 2.7%; and ADHD drugs 2.7%.
An estimated 12.6% of total adverse events could have been avoided if all drugs purchased from IOPs had instead been purchased from legal pharmacies during the period January 2017 to December 2022. These adverse events represent an estimated additional $67Bn cost for the U.S. healthcare system, in addition to the healthcare consequences for patients.
Assuming the drugs purchased through IOPs were sold legally in the U.S., the average annual economic value of these drugs between 2017 and 2022, using invoice level prices, is $28Bn, and aggregate value for the past six years totals $167Bn.
Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.
Navigate complex regulatory requirements with expert insights and bring transparency, efficiency and predictability to your regulatory affairs strategy.
Automate and standardize your regulatory management, from correspondence and commitments to registration and tracking.
